ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
September 11, 2024 12:07 ET
|
Oryzon Genomics, S.A.
MADRID and CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
September 09, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Exploring the triple combination with venetoclax and azacitidineStudy sponsored by Oregon Health & Science University (OHSU) MADRID and CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) --...
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications
September 03, 2024 08:00 ET
|
Oryzon Genomics, S.A.
In Australia, Malaysia and Mexico MADRID and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company...
ORYZON to Provide Corporate Progress Updates at Several Events in September
August 29, 2024 08:14 ET
|
Oryzon Genomics, S.A.
German Fall Conference 2024European College of Neuropsychopharmacology (ECNP) congress 2024Sachs Annual Biotech in Europe Forum 2024 MADRID, Spain and CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE...
ORYZON reports financial results and corporate update for half-year ending June 30, 2024
July 31, 2024 08:32 ET
|
Oryzon Genomics, S.A.
Company granted an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial with vafidemstat in Borderline Personality Disorder (BPD)Final data from PORTICO, global...
ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan
July 08, 2024 08:00 ET
|
Oryzon Genomics, S.A.
MADRID and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
June 28, 2024 09:28 ET
|
Oryzon Genomics, S.A.
All resolutions were approvedAdditional resolution to increase capital for up to 100 million euros approved42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 ...
ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference
June 26, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Selected for oral presentationConference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015,...
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
June 14, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activityA third cohort is ongoing following FDA’s OPTIMUS...
ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology
June 03, 2024 08:00 ET
|
Oryzon Genomics, S.A.
The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML)The combination showed substantial antileukemic...